Kervio Gaëlle, Ville Nathalie S, Leclercq Christophe, Daubert Jean-Claude, Carré François
Groupe de Recherche Cardio-Vasculaire, Université de Rennes 1, France.
Arch Phys Med Rehabil. 2004 Sep;85(9):1513-8. doi: 10.1016/j.apmr.2003.09.035.
To assess the intensity and daily reliability of the six-minute walk test (6MWT) in patients with moderate chronic heart failure (CHF).
Evaluation of testing protocol.
Hospitalized care.
CHF patients under optimal drug treatment (CHF-D, n=12) or optimal drug treatment plus multisite cardiac pacing (CHF-P, n=12).
Not applicable.
Peak values of oxygen uptake (VO2) and heart rate during a symptom-limited, treadmill exercise test and VO2, heart rate, and distance during 2 6MWT sessions (morning and afternoon). The 6MWT intensity was estimated by the ratio (%) of VO2 and heart rate values measured at the end of this test in relation to the respective peak values obtained during the treadmill exercise test.
Subjects' VO2 and heart rate during the 6MWT were lower (P<.001) and were about 90% of the peak values (VO2: CHF-D, 90.5%+/-11.1%; CHF-P, 93.0%+/-13.2%; heart rate: CHF-D, 90.6%+/-6.6%; CHF-P, 91.4%+/-9.6%). The distance walked during both 6MWT sessions did not differ significantly, with low coefficients of variation (< or =2.0%) and high intraclass correlation coefficients (> or =.98). In CHF-D only, the patients' VO2 and heart rate were significantly (P<.01, P<.05, respectively) higher during the afternoon session.
Despite an intensity significantly lower but close to that of the symptom-limited exercise test, the 6MWT was well tolerated in both CHF groups. In these populations, the 6MWT is reliable on a daily basis, for the distance walked. However, for assessing VO2 and heart rate values in CHF-D patients, the 6MWT must always be performed at the same time of day.
评估中度慢性心力衰竭(CHF)患者六分钟步行试验(6MWT)的强度及每日可靠性。
测试方案评估。
住院护理。
接受最佳药物治疗的CHF患者(CHF-D组,n = 12)或最佳药物治疗加多点心脏起搏的CHF患者(CHF-P组,n = 12)。
不适用。
症状限制的平板运动试验期间的摄氧量(VO2)峰值和心率,以及2次6MWT试验(上午和下午)期间的VO2、心率和步行距离。6MWT强度通过该试验结束时测得的VO2和心率值与平板运动试验期间获得的各自峰值的比率(%)来估计。
6MWT期间受试者的VO2和心率较低(P <.001),约为峰值的90%(VO2:CHF-D组,90.5%±11.1%;CHF-P组,93.0%±13.2%;心率:CHF-D组,90.6%±6.6%;CHF-P组,91.4%±9.6%)。两次6MWT试验期间的步行距离无显著差异,变异系数低(≤2.0%)且组内相关系数高(≥.98)。仅在CHF-D组中,下午试验期间患者的VO2和心率显著更高(分别为P <.01,P <.05)。
尽管6MWT的强度明显低于但接近症状限制运动试验的强度,两个CHF组对其耐受性良好。在这些人群中,6MWT在每日步行距离方面是可靠的。然而,对于评估CHF-D患者的VO2和心率值,6MWT必须始终在一天中的同一时间进行。